Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGJ398 with Chemotherapy in Advanced Solid Tumors and Cervical Cancer
NCT02312804Phase 1Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Jan 2015
- Primary completion
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of infigratinib in Cervical Cancer (CC) and solid tumor (2 arms), sponsored by UT Health San Antonio. Primary endpoint: Maximum Tolerated Dose at 12 months. Planned start Jan 2015; status: withdrawn.
02
Drugs
infigratinib
03
Conditions
Cervical Cancer (CC)solid tumor
Beyond the preview
Go deeper on NCT02312804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312804.